Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06781255 · ClinicalTrials.gov registry record · Phase 1
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
A Phase 1 study of Diabetic Macular Edema, sponsored by Michelle Abou-Jaoude.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06781255: Recruiting Phase 1 study of Diabetic Macular Edema, sponsored by Michelle Abou-Jaoude.
NCT06781255 is a Phase 1 study of Diabetic Macular Edema that is actively recruiting participants, run by Michelle Abou-Jaoude. The registered enrollment target is 5 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06781255, a Phase 1 study of Diabetic Macular Edema, is actively recruiting participants, sponsored by Michelle Abou-Jaoude.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
Primary Outcome
Frequency of participants experiencing ocular or systemic adverse events.
Conditions Studied
Interventions
- DRUG Kamuvudine-9
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT06781255 shows while recruiting
NCT06781255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Kamuvudine-9 is the first listed.
NCT06781255 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06781255 about?
NCT06781255 is a clinical study titled "Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)". A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).
What is the current status of trial NCT06781255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-03-13. Estimated completion is 2027-07.
What conditions does trial NCT06781255 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT06781255?
The interventions under investigation include: Kamuvudine-9 (DRUG).
Who is sponsoring clinical trial NCT06781255?
This trial is sponsored by Michelle Abou-Jaoude, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06781255 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06781255's enrollment target sits among peer trials
5 63rd of 63 higher than 1 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI